DZ2549A1 - Compositions pharmaceutiques contenant de l'hémisulfate d'élétriptan. - Google Patents

Compositions pharmaceutiques contenant de l'hémisulfate d'élétriptan.

Info

Publication number
DZ2549A1
DZ2549A1 DZ980159A DZ980159A DZ2549A1 DZ 2549 A1 DZ2549 A1 DZ 2549A1 DZ 980159 A DZ980159 A DZ 980159A DZ 980159 A DZ980159 A DZ 980159A DZ 2549 A1 DZ2549 A1 DZ 2549A1
Authority
DZ
Algeria
Prior art keywords
pct
pharmaceutical compositions
compositions containing
eletriptan hemisulfate
containing eletriptan
Prior art date
Application number
DZ980159A
Other languages
English (en)
Inventor
Valerie Denise Harding
Anne Billotte
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9714081.8A external-priority patent/GB9714081D0/en
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DZ2549A1 publication Critical patent/DZ2549A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DZ980159A 1997-07-03 1998-07-01 Compositions pharmaceutiques contenant de l'hémisulfate d'élétriptan. DZ2549A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9714081.8A GB9714081D0 (en) 1997-07-03 1997-07-03 Pharmaceutical compositions
GBGB9718270.3A GB9718270D0 (en) 1997-07-03 1997-08-28 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
DZ2549A1 true DZ2549A1 (fr) 2003-02-08

Family

ID=26311826

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980159A DZ2549A1 (fr) 1997-07-03 1998-07-01 Compositions pharmaceutiques contenant de l'hémisulfate d'élétriptan.

Country Status (31)

Country Link
US (1) US6166025A (fr)
EP (1) EP0999841B1 (fr)
JP (1) JP3350061B2 (fr)
CN (1) CN1145486C (fr)
AT (1) ATE206921T1 (fr)
AU (1) AU724728B2 (fr)
BG (1) BG103930A (fr)
BR (1) BR9810658A (fr)
CA (1) CA2292673C (fr)
DE (1) DE69802097T2 (fr)
DK (1) DK0999841T3 (fr)
DZ (1) DZ2549A1 (fr)
EA (1) EA002174B1 (fr)
ES (1) ES2163291T3 (fr)
HK (1) HK1029282A1 (fr)
HR (1) HRP990416B1 (fr)
HU (1) HUP0004468A3 (fr)
ID (1) ID24528A (fr)
IL (1) IL133206A0 (fr)
IS (1) IS5283A (fr)
MA (1) MA26518A1 (fr)
NO (1) NO312993B1 (fr)
NZ (1) NZ501419A (fr)
OA (1) OA11227A (fr)
PL (1) PL337803A1 (fr)
PT (1) PT999841E (fr)
SI (1) SI0999841T1 (fr)
SK (1) SK284462B6 (fr)
TR (1) TR199903332T2 (fr)
UY (1) UY25078A1 (fr)
WO (1) WO1999001135A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
WO2000064448A1 (fr) 1999-04-27 2000-11-02 Board Of Regents, The University Of Texas System Composition et methode permettant de traiter l'ischemie cerebrale
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CO5190664A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
IL136961A0 (en) * 1999-06-30 2001-06-14 Pfizer Prod Inc 5ht1 receptor agonists, caffeine and either a cox-2 inhibitor or nsaid for the treatment of migraine
CO5190678A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia combinada para el tratamiento de la migrana
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
WO2003020977A2 (fr) * 2001-08-31 2003-03-13 The University Court Of The University Of Glasgow Modulation des repetitions de nucleotides
US7404489B1 (en) 2003-03-04 2008-07-29 Qol Medical, Llc Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
CA2574518A1 (fr) * 2004-10-22 2006-04-27 Shin-Jen Shiao Composition pharmaceutique et cafe n'engendrant pas de dependence, comprenant de l'acide carboxylique comestible et/ou son sel acide et de la cafeine
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
JP2009504767A (ja) 2005-08-17 2009-02-05 フレミング・アンド・カンパニー・ファーマシューティカルズ ビタミンｂ１２鼻用スプレーおよび使用方法
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
WO2008095136A2 (fr) 2007-01-31 2008-08-07 Henkin Robert I Procédés de détection de substances biologiques
FR2926721B1 (fr) * 2008-01-30 2011-07-22 Philippe Perovitch Forme galenique pour l'adminsitration par voie trans-muqueuse de triptans
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
JP5776355B2 (ja) * 2010-07-16 2015-09-09 大正製薬株式会社 内服液剤
US8915245B2 (en) 2010-10-07 2014-12-23 Vapotherm, Inc. Nebulizer systems, apparatus and methods for respiratory therapy
JP5887893B2 (ja) * 2010-12-10 2016-03-16 大正製薬株式会社 内服液剤
JP5887894B2 (ja) * 2010-12-10 2016-03-16 大正製薬株式会社 内服液剤
WO2014143453A1 (fr) * 2013-03-15 2014-09-18 Henkin Robert I Traitement faisaint intervenir un inhibiteur de la phosphodiestérase
CN105592880B (zh) 2013-08-08 2018-10-26 蒸汽热能公司 呼吸治疗凝结物适配器
NL1040474C2 (en) * 2013-10-31 2015-05-04 Veramed B V Nasal compositions stimulating ciliary activity.
WO2015126944A1 (fr) 2014-02-18 2015-08-27 Henkin Robert I Procédés et compositions permettant de diagnostiquer et de traiter une perte et/ou une distorsion du goût ou de l'odorat
JP6097787B2 (ja) * 2015-06-09 2017-03-15 パル ファーマシューティカル， インコーポレーテッド 鼻内送達用シアノコバラミン低粘度水性製剤
FR3053334B1 (fr) * 2016-06-30 2018-07-27 L'oreal Melange liquide contenant du 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one et de compose de xanthine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
OA11227A (en) 2003-07-18
NO312993B1 (no) 2002-07-29
MA26518A1 (fr) 2004-12-20
NO995887D0 (no) 1999-12-01
AU724728B2 (en) 2000-09-28
HUP0004468A2 (hu) 2001-10-28
AU8856998A (en) 1999-01-25
DE69802097T2 (de) 2002-03-14
PL337803A1 (en) 2000-09-11
SI0999841T1 (fr) 2001-12-31
CA2292673C (fr) 2003-04-22
HRP990416B1 (en) 2002-04-30
IS5283A (is) 1999-11-30
HK1029282A1 (en) 2001-03-30
JP3350061B2 (ja) 2002-11-25
EP0999841B1 (fr) 2001-10-17
UY25078A1 (es) 2000-12-29
TR199903332T2 (xx) 2000-09-21
BR9810658A (pt) 2000-10-03
HUP0004468A3 (en) 2004-07-28
NZ501419A (en) 2000-09-29
ES2163291T3 (es) 2002-01-16
SK182899A3 (en) 2000-09-12
NO995887L (no) 2000-03-02
ATE206921T1 (de) 2001-11-15
WO1999001135A1 (fr) 1999-01-14
DE69802097D1 (de) 2001-11-22
CN1145486C (zh) 2004-04-14
SK284462B6 (sk) 2005-04-01
IL133206A0 (en) 2001-03-19
CA2292673A1 (fr) 1999-01-14
EP0999841A1 (fr) 2000-05-17
HRP990416A2 (en) 2000-04-30
PT999841E (pt) 2002-02-28
BG103930A (en) 2000-07-31
US6166025A (en) 2000-12-26
ID24528A (id) 2000-07-20
CN1261279A (zh) 2000-07-26
JP2000516262A (ja) 2000-12-05
DK0999841T3 (da) 2001-11-19
EA002174B1 (ru) 2002-02-28
EA199901100A1 (ru) 2000-08-28

Similar Documents

Publication Publication Date Title
DZ2549A1 (fr) Compositions pharmaceutiques contenant de l'hémisulfate d'élétriptan.
DE69727922D1 (de) Schnell zerfallende orale dosierungsform
ATE219765T1 (de) Indolderivate als cgmp-pde inhibitoren
MA27311A1 (fr) Utilisation d'inhibiteurs de cetp et facultativement d'inhibiteurs de hmg-coa-reductase et/ou d'agents antihypertensifs
IL133825A0 (en) Substituted 6-phenylphenanthridines, medicaments containing same and use thereof
HUT73807A (en) 5-ht1-like indole derivatives and pharmaceutical compositions containing them
MA27729A1 (fr) Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre
ATE310738T1 (de) Gesättigte 1,2-dithiaheterocyclische verbindungen enthaltende antivirale pharmazeutische zubereitungen
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
MA27731A1 (fr) Combinaison comprenant paroxetine et 2-(s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
FR2763592B1 (fr) Nouveaux derives glycosyles des ginkgolides, leur application en tant que medicaments et compositions pharmaceutiques les contenant
FR2700166B1 (fr) Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
AU2001237768A1 (en) Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
MY119643A (en) Pharmaceutical compositions containing eletriptan hemisulphate and caffeine
IT1314204B1 (it) Complessi di rutenio con elevata attivita' antitumorale
ECSP982578A (es) Composiciones farmaceuticas que contienen eletriptan hemisulfato